Janux Therapeutics Inc
JANX
NASDAQ
Biotechnology
$16.12
USD
+0.12 (+0.75%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $978.19M
Volume 441.5K
Revenue
$24.00M
TTM
+5367.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-102.59M
TTM
+2.9%
YoY
Operating Cash Flow
$-41.25M
TTM
+31.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 10.0 | 0.0 | 3.7 | 10.3 |
YoY Growth | -100.0% | +2177.9% | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 10.0 | 0.0 | 3.7 | 10.3 |
Selling, General & Administrative | 10.5 | 10.6 | 10.9 | 11.1 | 11.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 45.1 | 45.3 | 42.4 | 37.9 | 42.0 |
Operating Income | -45.1 | -35.3 | -42.4 | -34.2 | -31.7 |
EBITDA | -44.6 | -34.8 | -41.9 | -33.7 | -31.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 11.3 | 10.9 | 10.5 | 9.9 | 9.7 |
Income Before Income Taxes | -33.9 | -24.3 | -31.9 | -24.4 | -22.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -33.9 | -24.3 | -31.9 | -24.4 | -22.0 |
Consolidated Net Income / Loss | -33.9 | -24.3 | -31.9 | -24.4 | -22.0 |
Net Income Attributable to Common Shareholders | -33.9 | -24.3 | -31.9 | -24.4 | -22.0 |
Basic EPS | -$0.55 | -$0.39 | -$0.51 | -$0.39 | -$0.35 |
Diluted EPS | -$0.55 | -$0.39 | -$0.51 | -$0.39 | -$0.35 |
Basic Shares Outstanding | 61.9M | 62.0M | 62.2M | 62.7M | 62.9M |
Diluted Shares Outstanding | 61.9M | 62.0M | 62.2M | 62.7M | 62.9M |